Works matching IS 2160763X AND DT 2021 AND VI 10 AND IP 5

Results: 14

Relationship of the Calcitonin Gene‐Related Peptide Monoclonal Antibody Galcanezumab Pharmacokinetics and Capsaicin‐Induced Dermal Blood Flow in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 440, doi. 10.1002/cpdd.929

By:

Fiedler‐Kelly, Jill;
Raddad, Eyas;
Hoon, Jan;
Ludwig, Elizabeth A.;
Passarell, Julie;
Kielbasa, William;
Collins, Emily C.

Publication type:

Article

Comparison of Successful and Unsuccessful Cases of New Drug Approvals Based on the International Council on Harmonization E5 Guidelines in Japan.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 434, doi. 10.1002/cpdd.942

By:

Asada, Ryuta;
Shimizu, Shinobu;
Nakamura, Harumasa;
Ono, Shunsuke;
Yamaguchi, Takuhiro

Publication type:

Article

Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 453, doi. 10.1002/cpdd.938

By:

Bækdal, Tine A.;
Donsmark, Morten;
Hartoft‐Nielsen, Marie‐Louise;
Søndergaard, Flemming L.;
Connor, Alyson

Publication type:

Article

Hemodialysis Clearance of Enarodustat (JTZ‐951), an Oral Erythropoiesis Stimulating Agent, in Patients with End‐Stage Renal Disease.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 463, doi. 10.1002/cpdd.923

By:

Pai, Sudhakar M.;
Yamada, Hiroyuki

Publication type:

Article

A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, Three‐Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 521, doi. 10.1002/cpdd.896

By:

Sahota, Tarjinder;
Dota, Corina D.;
Vik, Torbjörn;
Yan, Weili;
Verheijen, Remy B.;
Walker, Stephen;
Li, Yan;
Goldwater, Ronald;
Ghiorghiu, Dana;
Mellemgaard, Anders;
Ahmed, Ghada F.

Publication type:

Article

Pharmacokinetics, Bioequivalence, and Safety Studies of Pantoprazole Sodium Enteric‐Coated Tablets in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 502, doi. 10.1002/cpdd.888

By:

Chen, Zhimin;
Gan, Fangliang;
Rao, Xiali;
Huang, Xiaoxiao;
Chen, Huafang

Publication type:

Article

Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 510, doi. 10.1002/cpdd.884

By:

Dawra, Vikas Kumar;
Pelletier, Kathleen;
Matschke, Kyle;
Shi, Haihong;
Hickman, Anne;
Zhou, Susan;
Krishna, Rajesh;
Sahasrabudhe, Vaishali

Publication type:

Article

A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 556, doi. 10.1002/cpdd.883

By:

Aliprantis, Antonios O.;
Wolford, Dennis;
Caro, Luzelena;
Maas, Brian M.;
Ma, Hua;
Montgomery, Diana L.;
Sterling, Laura M.;
Hunt, Allen;
Cox, Kara S.;
Vora, Kalpit A.;
Roadcap, Brad A.;
Railkar, Radha A.;
Lee, Andrew W.;
Stoch, S. Aubrey;
Lai, Eseng

Publication type:

Article

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 542, doi. 10.1002/cpdd.871

By:

Stass, Heino;
Feleder, Ethel;
Garcia‐Bournissen, Facundo;
Nagelschmitz, Johannes;
Weimann, Boris;
Yerino, Gustavo;
Altcheh, Jaime

Publication type:

Article

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 429, doi. 10.1002/cpdd.712
Publication type:: Article

Pharmacokinetics and Bioequivalence of 2 Immediate‐Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 535, doi. 10.1002/cpdd.864

By:

Li, Xin;
Liu, Lihua;
Deng, Yang;
Li, Yuan;
Zhang, Ping;
Wang, Yangyang;
Xu, Bing;
Feng, Jie;
Huang, Lu

Publication type:

Article

First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 471, doi. 10.1002/cpdd.869

By:

Ye, Ying;
Gaudy, Allison;
Schafer, Peter;
Thomas, Michael;
Weiss, Daniel;
Chen, Nianhang;
Liu, Liangang;
Xue, Yongjun;
Carayannopoulos, Leon;
Palmisano, Maria

Publication type:

Article

Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 486, doi. 10.1002/cpdd.851

By:

Liu, Hongzhong;
Jiang, Ji;
Chen, Zhaozhao;
Zhang, Yunhui;
Li, Jinyi;
Hoechel, Joachim;
Rohde, Beate;
Zimmermann, Torsten;
Schultze‐Mosgau, Marcus‐Hillert

Publication type:

Article

Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 494, doi. 10.1002/cpdd.872

By:

Lissy, Michael;
Demmel, Valentin;
Sachse, Richard;
Ammer, Nicola;
Kelepouris, Nicky;
Ostrow, Vlady

Publication type:

Article